ZA202107346B - Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity - Google Patents
Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunityInfo
- Publication number
- ZA202107346B ZA202107346B ZA2021/07346A ZA202107346A ZA202107346B ZA 202107346 B ZA202107346 B ZA 202107346B ZA 2021/07346 A ZA2021/07346 A ZA 2021/07346A ZA 202107346 A ZA202107346 A ZA 202107346A ZA 202107346 B ZA202107346 B ZA 202107346B
- Authority
- ZA
- South Africa
- Prior art keywords
- autoimmunity
- inflammation
- pain
- prophylaxis
- treatment
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title abstract 4
- 230000005784 autoimmunity Effects 0.000 title abstract 4
- 230000004054 inflammatory process Effects 0.000 title abstract 4
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title 1
- IEZYYUGASWTPRJ-UHFFFAOYSA-N N-[2-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propyl]-3-phenylpropanamide Chemical compound OC1=CC=C(C=C1)C(CNC(CCC1=CC=CC=C1)=O)COCC(C)O IEZYYUGASWTPRJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 230000003040 nociceptive effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19153315 | 2019-01-23 | ||
| PCT/EP2020/051528 WO2020152226A1 (en) | 2019-01-23 | 2020-01-22 | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202107346B true ZA202107346B (en) | 2023-10-25 |
Family
ID=65228356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2021/07346A ZA202107346B (en) | 2019-01-23 | 2021-09-23 | Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11891350B2 (enExample) |
| EP (1) | EP3860582B1 (enExample) |
| JP (2) | JP7611148B2 (enExample) |
| KR (1) | KR20210119403A (enExample) |
| CN (1) | CN113329746B (enExample) |
| AU (1) | AU2020210831B2 (enExample) |
| BR (1) | BR112021019476A2 (enExample) |
| CA (1) | CA3118996A1 (enExample) |
| DK (1) | DK3860582T3 (enExample) |
| ES (1) | ES2913977T3 (enExample) |
| IL (1) | IL282718B2 (enExample) |
| PL (1) | PL3860582T3 (enExample) |
| PT (1) | PT3860582T (enExample) |
| RS (1) | RS63270B1 (enExample) |
| SG (1) | SG11202111773QA (enExample) |
| WO (1) | WO2020152226A1 (enExample) |
| ZA (1) | ZA202107346B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3939578A1 (en) * | 2020-07-13 | 2022-01-19 | Novaremed Ltd. | Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease |
| WO2026037478A1 (en) | 2023-08-11 | 2026-02-19 | Novaremed AG | (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7642290B2 (en) | 2002-10-03 | 2010-01-05 | Novaremed Limited | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection |
| US7674829B2 (en) | 2004-03-26 | 2010-03-09 | Novaremed Limited | Compounds for the treatment of AIDS and other viral diseases |
| GB0804213D0 (en) | 2008-03-06 | 2008-04-16 | New Era Biotech Ltd | A method of printing or preventing pain |
| WO2011030205A1 (en) | 2009-09-09 | 2011-03-17 | Novaremed Ltd. | N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation |
| US8802734B2 (en) | 2009-09-09 | 2014-08-12 | Novaremed Limited | Method of treating or preventing pain |
| GB0916073D0 (en) | 2009-09-14 | 2009-10-28 | Cintec Int Ltd | Improvements in and relating to building anchor systems |
| CN103998420B (zh) * | 2011-12-08 | 2018-04-17 | 诺瓦麦有限公司 | (s)2‑n(3‑o‑(丙‑2‑醇)‑1‑丙基‑4‑羟基苯)‑3‑苯基丙酰胺的分离的立体异构形式 |
-
2020
- 2020-01-22 RS RS20220510A patent/RS63270B1/sr unknown
- 2020-01-22 KR KR1020217023524A patent/KR20210119403A/ko not_active Ceased
- 2020-01-22 BR BR112021019476A patent/BR112021019476A2/pt unknown
- 2020-01-22 PT PT207031527T patent/PT3860582T/pt unknown
- 2020-01-22 SG SG11202111773QA patent/SG11202111773QA/en unknown
- 2020-01-22 US US17/295,788 patent/US11891350B2/en active Active
- 2020-01-22 AU AU2020210831A patent/AU2020210831B2/en active Active
- 2020-01-22 CA CA3118996A patent/CA3118996A1/en active Pending
- 2020-01-22 DK DK20703152.7T patent/DK3860582T3/da active
- 2020-01-22 JP JP2021543276A patent/JP7611148B2/ja active Active
- 2020-01-22 ES ES20703152T patent/ES2913977T3/es active Active
- 2020-01-22 EP EP20703152.7A patent/EP3860582B1/en active Active
- 2020-01-22 CN CN202080010393.8A patent/CN113329746B/zh active Active
- 2020-01-22 IL IL282718A patent/IL282718B2/en unknown
- 2020-01-22 PL PL20703152.7T patent/PL3860582T3/pl unknown
- 2020-01-22 WO PCT/EP2020/051528 patent/WO2020152226A1/en not_active Ceased
-
2021
- 2021-09-23 ZA ZA2021/07346A patent/ZA202107346B/en unknown
-
2024
- 2024-12-23 JP JP2024226332A patent/JP2025036479A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3860582T (pt) | 2022-07-08 |
| ES2913977T3 (es) | 2022-06-07 |
| KR20210119403A (ko) | 2021-10-05 |
| SG11202111773QA (en) | 2021-11-29 |
| US20220002228A1 (en) | 2022-01-06 |
| CA3118996A1 (en) | 2020-07-30 |
| US11891350B2 (en) | 2024-02-06 |
| JP7611148B2 (ja) | 2025-01-09 |
| JP2025036479A (ja) | 2025-03-14 |
| RS63270B1 (sr) | 2022-06-30 |
| EP3860582A1 (en) | 2021-08-11 |
| IL282718A (en) | 2021-06-30 |
| PL3860582T3 (pl) | 2022-08-01 |
| JP2022518288A (ja) | 2022-03-14 |
| AU2020210831B2 (en) | 2025-02-13 |
| BR112021019476A2 (pt) | 2021-11-30 |
| EP3860582B1 (en) | 2022-05-04 |
| CN113329746A (zh) | 2021-08-31 |
| IL282718B1 (en) | 2024-04-01 |
| WO2020152226A1 (en) | 2020-07-30 |
| IL282718B2 (en) | 2024-08-01 |
| CN113329746B (zh) | 2025-05-02 |
| AU2020210831A1 (en) | 2021-05-20 |
| DK3860582T3 (da) | 2022-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4371554A3 (en) | Use of sublingual dexmedetomidine for the treatment of agitation | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| UA114528C2 (uk) | Комбінації активних сполук, що містять карбоксамідні похідні та засіб біологічної боротьби | |
| MX2025000166A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo | |
| WO2019246262A3 (en) | Methods of treating or inhibiting onset of huntington's disease | |
| WO2019157495A3 (en) | Methods for preventing and/or treating bone loss conditions by modulating irisin | |
| MX346208B (es) | Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida. | |
| PH12016500668A1 (en) | Active compound combinations comprising a (thio)carboxamide derivative and a fungicidal compound | |
| MX2013008729A (es) | Metodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales. | |
| MX2022006533A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo. | |
| NZ731850A (en) | System and method for preventing alopecia | |
| MX2021007161A (es) | Agente que contiene acido ursodesoxicolico para tratar o prevenir la presbicia. | |
| PH12017501110B1 (en) | Active compound combinations comprising a (thio)carboxamide derivative and fungicidal compound(s) | |
| TW201613583A (en) | Laquinimod for the treatment of relapsing- remitting multiple sclerosis (RRMS) patients with a high disability status | |
| WO2020016655A3 (en) | Treatment of neuropathy with dna constructs expressing igf-1 isoforms | |
| MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| PH12020551179A1 (en) | Methods for treating mitochondrial disorder | |
| WO2020079489A3 (en) | Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs | |
| EA024696B9 (ru) | Способ обработки волос | |
| MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
| MX2020001164A (es) | Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico. | |
| MX2025015454A (es) | Formulaciones/composiciones que comprenden ibrutinib | |
| BR112021019476A2 (pt) | Compostos para uso no tratamento ou profilaxia de dor, inflamação e / ou autoimunidade | |
| MX2019012050A (es) | Composicion para usar en el tratamiento de la epilepsia. |